AIRNA Valuation, Funding & Investors

Beacon Therapeutics is a London-headquartered gene therapy company targeting inherited retinal diseases causing blindness. The firm advances GT005, an AAV-delivered therapy for wet AMD choroidal neovascularization, with Phase 2b trials ongoing in the United States and Europe following seed funding from Oxford Nanopore founders.

Convergent Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that develops radiopharmaceuticals for cancer treatment. Its lead program, CONV01-alpha, is a radioantibody that binds to prostate-specific membrane antigen to deliver a radioactive payload selectively to prostate cancer cells while sparing healthy tissue. The company is building a broader pipeline of similar radioantibody therapies targeting prostate cancer and other solid tumors.

Unlearn.AI is a clinical trial platform generating digital twins of patients using machine learning models trained on historical data. Its TwinRCT design accelerates biopharma studies by reducing required participants while maintaining statistical power for endpoints. Headquartered in San Francisco, the company partners with Pfizer and Roche on trials for Alzheimer's and oncology indications.

Ildong Pharmaceutical Co Ltd is a Korean company which is engaged in manufacturing pharmaceutical products. Its product portfolio includes generic drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, antihistamines, antipyretics, analgesics, respiratory medications, endocrine medications, psycho-neurological medications, dermatological medications, urologic medications, antibiotics and others. The company also provides raw materials such as synthesizes, probiotics and others.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Planet, Investments, and others. The majority of its revenue is generated from the planet segment. The geographical segments are UAE, Other GCC countries, and Other countries.

Theracos is a Marlborough, Massachusetts-based pharmaceutical company founded in 2000, advancing oral antidiabetic agents and therapies for metabolic disorders. Its pipeline includes Bexagliflozin, a SGLT2 inhibitor in Phase III for type 2 diabetes and chronic kidney disease, partnered with Janssen. Theracos leverages expertise in formulation and clinical trial execution across toxicology and regulatory domains.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Kumquat Biosciences is a San Diego-headquartered biopharmaceutical company advancing targeted cancer therapies through small-molecule inhibitors. Its pipeline targets KRAS mutations and DNA damage response pathways, with lead candidates entering Phase I trials for solid tumors. The firm leverages structure-based drug design and proprietary assays to develop orally bioavailable compounds. Kumquat Biosciences collaborates with academic institutions in California, focusing on precision oncology for lung, pancreatic, and colorectal cancers.

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.